Laurie Bartlett Keating joined Alnylam in 2014 with more than 25 years of executive experience at high-growth technology and biotechnology companies.
Prior to joining Alnylam, Laurie served as Senior Vice President, General Counsel and Secretary of Millennium: The Takeda Oncology Company for 9 years, responsible for setting the company’s global legal, intellectual property, and corporate quality strategies and priorities. Prior to Millennium, Laurie was co-founder and the first CEO of Hydra Biosciences, Inc. Before co-founding Hydra, she served as an executive at high-growth technology companies, including Iomega Corporation, and Sybase, Inc., a software company that grew from a few hundred to 6,000 employees during Laurie’s tenure on the management team. Based on her leadership at Sybase, Laurie was named one of the 45 most influential in-house lawyers in the United States under the age of 45. Upon graduating from law school, Laurie practiced law at McCutchen, Doyle, Brown and Enersen (which became Bingham McCutchen and is now a part of Morgan, Lewis & Bockius) in San Francisco.
She has a Doctor of Jurisprudence degree from the University of California, Hastings College of the Law, and a BA in Economics from the University of California at Berkeley. Laurie is a member of the Board of Directors of Immuneering Corporation and MassBIO, a former member of the Board of Hydra Biosciences, and a past chair of the BIO General Counsels Committee.
What is Laurie Keating's net worth?
The estimated net worth of Laurie Keating is at least $3.50 million as of May 16th, 2022. Ms. Keating owns 14,000 shares of Alnylam Pharmaceuticals stock worth more than $3,497,900 as of November 21st. This net worth approximation does not reflect any other investments that Ms. Keating may own. Learn More about Laurie Keating's net worth.
How do I contact Laurie Keating?
Has Laurie Keating been buying or selling shares of Alnylam Pharmaceuticals?
Laurie Keating has not been actively trading shares of Alnylam Pharmaceuticals during the last quarter. Most recently, Laurie Keating sold 10,000 shares of the business's stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $188.95, for a transaction totalling $1,889,500.00. Following the completion of the sale, the executive vice president now directly owns 13,008 shares of the company's stock, valued at $2,457,861.60. Learn More on Laurie Keating's trading history.
Who are Alnylam Pharmaceuticals' active insiders?
Alnylam Pharmaceuticals' insider roster includes Dennis Ausiello (Director), Michael Bonney (Director), Jeffrey Dunn (CEO), Kevin Fitzgerald (EVP), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Amy Schulman (Director), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?
In the last year, insiders at the biopharmaceutical company sold shares 11 times. They sold a total of 154,848 shares worth more than $34,733,444.48. The most recent insider tranaction occured on August, 20th when CEO Yvonne Greenstreet sold 15,000 shares worth more than $4,200,000.00. Insiders at Alnylam Pharmaceuticals own 1.5% of the company.
Learn More about insider trades at Alnylam Pharmaceuticals. Information on this page was last updated on 8/20/2024.
